A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

NCT05711628 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped Other - Protocol moved to Withdrawn

Conditions

Recurrent Classic Hodgkin Lymphoma
Refractory Classic Hodgkin Lymphoma

Interventions

PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation
DRUG: Bendamustine
DRUG: Brentuximab Vedotin
DRUG: Carboplatin
PROCEDURE: Computed Tomography
DRUG: Etoposide
DRUG: Gemcitabine
DRUG: Ifosfamide
DRUG: Pegylated Liposomal Doxorubicin Hydrochloride
BIOLOGICAL: Pembrolizumab
PROCEDURE: Positron Emission Tomography
RADIATION: Radiation Therapy
OTHER: Transplant Conditioning
DRUG: Vinorelbine

Sponsor

National Cancer Institute (NCI)